Results 141 to 150 of about 3,342 (167)

Pre‐Seasonal Treatment With Recombinant Carrier‐Based Birch Vaccine Improves Birch Pollen Allergy

open access: yesAllergy, Volume 81, Issue 11, Page 3985-4004, November 2026.
We conducted a two stage SCIT trial with GNR‐127 containing a recombinant fusion protein consisting of Bet v 1 and Mal d 1‐derived peptides fused to PreS from HBV. Stage 1 identified two safe maximum tolerated doses (40 μg and 80 μg). In the following Stage 2, five preseasonal injections were well tolerated, induced dose‐dependent allergen‐specific IgG,
Musa R. Khaitov   +43 more
wiley   +1 more source

Review Article: Fibrosis Reversal in Metabolic Dysfunction‐Associated Steatohepatitis—The Promise of Emerging Therapeutics

open access: yesAlimentary Pharmacology &Therapeutics, Volume 64, Issue 9, Page 1184-1196, November 2026.
Metabolic dysfunction‐associated steatohepatitis is the second commonest US indication for liver transplantation but remains largely undiagnosed and untreated. Fibrosis stage is the strongest predictor of major adverse liver outcomes, with decompensation rates and transplant‐free survival diverging sharply between F3 and F4, while cardiovascular ...
Malek Ayoub   +2 more
wiley   +1 more source

HLA‐A*11:01 Identifies Patients at Risk for Persistent Viraemia and Advanced Fibrosis in HDV Infection

open access: yesAlimentary Pharmacology &Therapeutics, Volume 64, Issue 10, Page 1432-1447, November 2026.
The HLA‐A*11:01 allele is associated with persistent viraemia and advanced liver fibrosis in HDV infection. HLA‐A*11:01 carriers exhibit a reduced T‐cell repertoire, suggesting a narrower T‐cell response to the infection. ABSTRACT Background Hepatitis delta virus (HDV) infection causes the most severe form of viral hepatitis, with highly heterogeneous ...
Maria Francesca Cortese   +11 more
wiley   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 22, Page 6574-6606, November 2026.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown   +2 more
wiley   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 22, Page 6607-6626, November 2026.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Transplantation of Hepatitis B Surface Antigen Positive or Viremic Kidneys: A Systematic Review and Meta‐Analysis

open access: yesClinical Transplantation, Volume 40, Issue 11, November 2026.
ABSTRACT Purpose This systematic review and meta‐analysis examines the evidence related to the use of HBV positive kidneys into non‐viremic kidney transplant recipients (KTRs). Methods We searched PubMed and Embase through November 2025 and identified studies of recipients of hepatitis B surface antigen positive (HBsAg+) or viremic kidneys.
Dhruv Ahuja   +6 more
wiley   +1 more source

Abstract Supplement HIV Glasgow 8–11 November 2026, Glasgow, UK/Virtual

open access: yes
Journal of the International AIDS Society, Volume 29, Issue S6, November 2026.
wiley   +1 more source

The Oncologic Burden of Hepatitis C Virus Infection: A Clinical Perspective

Ca-A Cancer Journal for Clinicians, 2017
Felipe Samaniego   +2 more
exaly  

Hepatitis C Viraemia and Liver Disease in Symptom-Free Individuals With Anti-HCV

Lancet, The, 1992
Alfredo Alberti   +2 more
exaly  

Home - About - Disclaimer - Privacy